AJANTPHARM Share Price Target 2035

CAGR-based price projection for Ajanta Pharma Limited (AJANTPHARM) targeting 2035, derived from official NSE exchange closing prices.

Bear Case (11.0% CAGR)
Rs 9,196
2035 Target
Base Case (27.6% CAGR)
Rs 32,155
2035 Target
Bull Case (81.7% CAGR)
Rs 774,076
2035 Target

Current Market Snapshot

CMP: Rs 3,581.00
52W High: Rs 3,718.20
52W Low: Rs 2,756.00
1Y CAGR: 62.9%
3Y CAGR: 27.6%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 3,977 Rs 4,570 Rs 6,508
2028 Rs 4,416 Rs 5,832 Rs 11,826
2029 Rs 4,904 Rs 7,443 Rs 21,491
2030 Rs 5,446 Rs 9,499 Rs 39,056
2031 Rs 6,047 Rs 12,122 Rs 70,975
2032 Rs 6,715 Rs 15,470 Rs 128,980
2033 Rs 7,457 Rs 19,743 Rs 234,393
2034 Rs 8,281 Rs 25,196 Rs 425,955
2035 Rs 9,196 Rs 32,155 Rs 774,076

Other AJANTPHARM Price Targets

2025 2026 2027 2028 2030 2040 2050

Frequently Asked Questions

What is the AJANTPHARM share price target for 2035?

Based on historical growth analysis, the AJANTPHARM share price target for 2035 ranges from Rs 9,196 (conservative) to Rs 32,155 (base case) to Rs 774,076 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of AJANTPHARM?

The current market price of AJANTPHARM (Ajanta Pharma Limited) is Rs 3,581.00. The 52-week high is Rs 3,718.20 and 52-week low is Rs 2,756.00.

Is AJANTPHARM a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for AJANTPHARM price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 11.0% CAGR), Base (27.6% CAGR), and Bull (optimistic at 81.7% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.